We are pleased to announce that the second phase of the Rethinking Alzheimer's disease project kicks off! Rethinking Alzheimer's Disease, coordinated by EBC, in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), is a research-driven project offering policy recommendations to make tangible changes with the aim to improve the lives of [...]
EBC is pleased to be part of the session “Diagnosis, diagnostic tools and cognitive assessments” at the upcoming 36th Global Conference of Alzheimer’s Disease International. The session will take place on 26 April 2024 at 13:30-15:00 in Krakow (Poland). Prof. Giovanni Frisoni will present "Rethinking Alzheimer's disease: Scaling up health systems' readiness" as one [...]
Save the date for the virtual event Rethinking Alzheimer’s disease: Moving towards a new Alzheimer’s disease detection and diagnosis pathway in Sweden, set to take place on 26 September 2023 at 10:00 – 12:00 (Brussels time)! About Alzheimer’s disease Alzheimer’s disease (AD) is a neurodegenerative disease that progresses in stages, beginning with a long silent phase [...]
Registration is now open for the launch event of the RETHINKING Alzheimer's disease White Paper, taking place virtually on 24 January 2023 at 12:30 – 14:00. The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), will present its White Paper “RETHINKING Alzheimer’s disease: Detection and diagnosis“. This paper [...]
The launch event of the RETHINKING Alzheimer’s disease White Paper, calling for change in Alzheimer’s care, will take place virtually on 24 January 2023 at 12:30 – 14:00. The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), will present its White Paper “RETHINKING Alzheimer’s disease: Detection and diagnosis“. This paper is [...]
Through RETHINKING Alzheimer’s disease (AD), the European Brain Council (EBC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) are joining forces with the ambition of improving Alzheimer’s disease care pathway and the lives of people living with it. Officially launched on 29 April 2022, the project kicked off its operational activities with [...]
